RICTOR and small cell lung carcinoma: Additionally, RICTOR has been identified as the most frequently amplified gene in a cohort of metastatic, small, cell lung cancer (SCLC) patients (~14% of patients) and SCLC patients, with RICTOR amplification having a significantly decreased overall survival [9].